317 related articles for article (PubMed ID: 19318328)
1. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
2. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
[TBL] [Abstract][Full Text] [Related]
4. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
Kiss A; Wang NJ; Xie JP; Thorgeirsson SS
Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis.
Wang W; Yang LY; Huang GW; Lu WQ; Yang ZL; Yang JQ; Liu HL
Br J Cancer; 2004 Jun; 90(12):2349-55. PubMed ID: 15150600
[TBL] [Abstract][Full Text] [Related]
6. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
7. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis.
Abou-Elella A; Gramlich T; Fritsch C; Gansler T
Mod Pathol; 1996 Feb; 9(2):95-8. PubMed ID: 8657726
[TBL] [Abstract][Full Text] [Related]
8. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma.
Cheung ST; Leung KL; Ip YC; Chen X; Fong DY; Ng IO; Fan ST; So S
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):551-6. PubMed ID: 15701840
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.
Zhang T; Sun HC; Xu Y; Zhang KZ; Wang L; Qin LX; Wu WZ; Liu YK; Ye SL; Tang ZY
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8557-63. PubMed ID: 16361537
[TBL] [Abstract][Full Text] [Related]
10. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
[TBL] [Abstract][Full Text] [Related]
12. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization.
Miyasaka Y; Enomoto N; Nagayama K; Izumi N; Marumo F; Watanabe M; Sato C
Br J Cancer; 2001 Jul; 85(2):228-34. PubMed ID: 11461082
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
14. Functional genomics of hepatocellular carcinoma.
Thorgeirsson SS; Lee JS; Grisham JW
Hepatology; 2006 Feb; 43(2 Suppl 1):S145-50. PubMed ID: 16447291
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-kit protooncogene in human hepatocellular carcinoma.
Chung CY; Yeh KT; Hsu NC; Chang JH; Lin JT; Horng HC; Chang CS
Cancer Lett; 2005 Jan; 217(2):231-6. PubMed ID: 15617841
[TBL] [Abstract][Full Text] [Related]
16. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma.
Nissom PM; Lo SL; Lo JC; Ong PF; Lim JW; Ou K; Liang RC; Seow TK; Chung MC
FEBS Lett; 2006 Apr; 580(9):2216-26. PubMed ID: 16574106
[TBL] [Abstract][Full Text] [Related]
17. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
[TBL] [Abstract][Full Text] [Related]
18. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
[TBL] [Abstract][Full Text] [Related]
19. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
Chan KL; Guan XY; Ng IO
Hum Pathol; 2004 Nov; 35(11):1324-31. PubMed ID: 15668888
[TBL] [Abstract][Full Text] [Related]
20. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
